5-氨基吲哚-2-甲酸乙酯 | 71086-99-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-氨基吲哚-2-甲酸乙酯
• 中文别名: 5-氨基-2-吲哚羧酸；5-氨基-2-吲哚 羧酸
• 英文名称: ethyl 5-amino-1H-indole-2-carboxylate
• 英文别名: ethyl 5-aminoindole-2-carboxylate；5-amino-1H-indole-2-carboxylic acid ethyl ester
• CAS: 71086-99-2
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.228
• InChiKey: WCGCOZXVVVIAEF-UHFFFAOYSA-N

物化性质

• 熔点：
  126-127 °C
• 沸点：
  420.1±25.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  68.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  室温和干燥环境下保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 5-amino-1H-indole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 5-amino-1H-indole-2-carboxylate
CAS number: 71086-99-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H12N2O2
Molecular weight: 204.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氨基吲哚-2-甲酸乙酯 在 吡啶 、 4-二甲氨基吡啶 、 sodium hydroxide 、 2,4-滴二甲胺盐 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 121.0h， 生成 比折来新
  参考文献：
  名称：

  Synthesis and DNA crosslinking by a rigid CPI dimer

  摘要：

  DOI：

  10.1021/ja00023a085
• 作为产物：
  描述：

  在 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 5-氨基吲哚-2-甲酸乙酯
  参考文献：
  名称：

  5-(取代碳酰氨基)-1H-吲哚-2-碳酰肼衍生物 及其制备方法和应用

  摘要：

  5‑(取代碳酰氨基)‑1H‑吲哚‑2‑碳酰肼衍生物及其制备方法和应用。制备方法：1)合成中间体丙酮酸乙酯对硝基苯腙；2)制备中间体5‑硝基吲哚‑2‑羧酸乙酯；3)制备中间体5‑氨基‑1H‑吲哚‑2‑羧酸乙酯；4)制备中间体5‑(取代碳酰氨基)‑1H‑吲哚‑2‑羧酸乙酯；5)制备中间体5‑(取代碳酰氨基)‑1H‑吲哚‑2‑碳酰肼；6)制备N'‑取代亚甲基‑5‑(取代碳酰氨基)‑1H‑吲哚‑2‑碳酰肼衍生物。所述一类N'‑取代亚甲基‑5‑(取代碳酰氨基)‑1H‑吲哚‑2‑碳酰肼衍生物可在制备预防或治疗涉及CDK9受体相关疾病药物中应用。反应成本低，产率高，反应过程简单易控制，具有抗癌活性。

  公开号：

  CN104860866B

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors
  作者：Hongyu Hu、Jun Wu、Mingtao Ao、Xiaoping Zhou、Boqun Li、Zhenzhen Cui、Tong Wu、Lijuan Wang、Yuhua Xue、Zhen Wu、Meijuan Fang

  DOI：10.1016/j.bioorg.2020.104064

  日期：2020.9

  previous work on the investigation of CDK9 inhibitors bearing indole moiety for the discovery of novel anticancer agents, novel methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold were designed, synthesized, and evaluated for the CDK9 inhibitory activity and anticancer activity. Biological activity results demonstrated that most of these derivatives

  在我们以前的研究中，为了发现新型抗癌药，研究了带有吲哚部分的CDK9抑制剂，即具有（5-（（4-（吡啶-3-基）嘧啶-2-基）氨基）-1 H-吲哚支架的设计，合成及对CDK9抑制活性和抗癌活性的评估，生物学活性结果表明，这些衍生物大多数对CDK9的激酶活性具有良好的抑制作用，例如阻断其磷酸化功能和抑制其活性。抑制HIV-1转录化合物12i被发现是最有效的CDK9抑制剂，对HepG2，A375，MCF-7和A549表现出优异的抗癌活性，但对包括HaCaT和MCF-10A在内的正常细胞毒性较低。进一步的研究表明，由于CDK9抑制和随后抑制RNAPII CTD的丝氨酸2磷酸化的结果，代表性化合物12i剂量依赖性地增加了裂解的PARP水平，通过诱导癌细胞凋亡来发挥其抗增殖作用。最后，分子对接分析表明12i与CDK9具有良好的结合亲和力。总之，12i是有效的CDK9抑制剂，可以被认为是开发潜在抗癌药物的良好候选铅。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20130023502A1

  公开（公告）日：2013-01-24

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶化合物， 其中环A是一个含有五个成员的饱和或不饱和碳环，该环可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组成， 其中R1、R2、R4、R3、R5和R6如权利要求书中所定义，并且环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药用盐、二对映体、对映体、消旋体、水合物和溶剂化合物。
• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。